8.06% of Aptevo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Aptevo Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/15/2024	Armistice Capital LLC	749,234	$0.23M	0.0%	N/A	18.359%
11/15/2023	Sabby Management LLC	1,334,169	$0.44M	0.3%	N/A	11.581%
11/15/2023	Armistice Capital LLC	1,235,000	$0.41M	0.0%	N/A	10.717%
2/1/2023	Bank of Montreal Can	10,000	$61K	0.0%	N/A	0.196%
11/15/2022	Cantor Fitzgerald L. P.	133,700	$0.41M	0.0%	N/A	2.627%
11/7/2022	Virtu Financial LLC	28,421	$86K	0.0%	+122.6%	0.558%
12/10/2021	Towercrest Capital Management	211,227	$3.26M	0.6%	N/A	4.313%
12/8/2021	Moors & Cabot Inc.	389,269	$3.73M	0.2%	N/A	7.948%
11/15/2021	Franklin Resources Inc.	15,650	$0.24M	0.0%	N/A	0.320%
11/15/2021	GSA Capital Partners LLP	13,651	$0.21M	0.0%	N/A	0.279%
11/12/2021	Renaissance Technologies LLC	143,419	$2.21M	0.0%	-10.3%	2.931%
11/9/2021	BlackRock Inc.	55,394	$0.86M	0.0%	+1.9%	1.133%
11/5/2021	Moors & Cabot Inc.	389,269	$3.73M	0.3%	N/A	7.954%
8/17/2021	Balyasny Asset Management LLC	18,012	$0.40M	0.0%	-70.6%	0.405%
8/17/2021	Boothbay Fund Management LLC	15,350	$0.34M	0.0%	+4.9%	0.345%
8/16/2021	Alyeska Investment Group L.P.	139,172	$3.12M	0.0%	-80.9%	3.127%
8/16/2021	Morgan Stanley	8,364	$0.19M	0.0%	+163.4%	0.188%
8/16/2021	Kennedy Capital Management Inc.	187,995	$4.22M	0.1%	N/A	4.225%
8/16/2021	State Street Corp	10,973	$0.25M	0.0%	N/A	0.247%
8/13/2021	Renaissance Technologies LLC	159,923	$3.59M	0.0%	-23.6%	3.594%
8/13/2021	Anson Funds Management LP	35,587	$0.80M	0.1%	-26.6%	0.800%
8/13/2021	Northern Trust Corp	22,652	$0.51M	0.0%	+170.7%	0.509%
8/13/2021	QS Investors LLC	15,650	$0.35M	0.0%	+37.3%	0.352%
8/13/2021	Geode Capital Management LLC	38,917	$0.87M	0.0%	+8.8%	0.875%
8/13/2021	Vanguard Group Inc.	134,760	$3.02M	0.0%	+2.9%	3.028%
5/17/2021	Schonfeld Strategic Advisors LLC	9,700	$0.30M	0.0%	-12.6%	0.218%
5/14/2021	RTW Investments LP	281,402	$8.59M	0.1%	-2.4%	6.324%
5/14/2021	Dynamic Technology Lab Private Ltd	14,022	$0.43M	0.0%	+6.2%	0.315%
5/13/2021	QS Investors LLC	11,400	$0.35M	0.0%	N/A	0.256%
5/13/2021	JBF Capital Inc.	3,907	$0.12M	0.0%	+49.9%	0.088%
5/13/2021	Renaissance Technologies LLC	209,223	$6.39M	0.0%	-17.8%	4.702%
5/13/2021	Bank of New York Mellon Corp	9,964	$0.31M	0.0%	N/A	0.224%
5/13/2021	Bank of Montreal Can	25,280	$0.67M	0.0%	-20.1%	0.568%
5/12/2021	Geode Capital Management LLC	35,762	$1.09M	0.0%	+26.8%	0.804%
5/7/2021	BlackRock Inc.	57,605	$1.76M	0.0%	-1.0%	1.294%
3/8/2021	Dimensional Fund Advisors LP	5,502	$0.20M	0.0%	N/A	0.126%
2/25/2021	Dimensional Fund Advisors LP	5,502	$0.20M	0.0%	N/A	0.126%
2/24/2021	Alyeska Investment Group L.P.	49,601	$1.82M	0.0%	N/A	1.133%
2/18/2021	Ghost Tree Capital LLC	50,000	$1.83M	0.4%	N/A	1.142%
2/16/2021	Alyeska Investment Group L.P.	49,601	$1.82M	0.0%	N/A	1.133%
2/16/2021	Pura Vida Investments LLC	8,203	$0.30M	0.0%	N/A	0.187%
2/16/2021	Price T Rowe Associates Inc. MD	6,300	$0.23M	0.0%	N/A	0.144%
2/12/2021	Stonepine Capital Management LLC	18,280	$0.67M	0.5%	N/A	0.417%
2/11/2021	JBF Capital Inc.	2,607	$96K	0.0%	N/A	0.060%
2/11/2021	Northern Trust Corp	8,707	$0.32M	0.0%	N/A	0.199%
2/11/2021	Citigroup Inc.	967	$35K	0.0%	N/A	0.022%
2/11/2021	Dynamic Technology Lab Private Ltd	13,202	$0.48M	0.1%	N/A	0.301%
2/10/2021	Renaissance Technologies LLC	254,423	$9.33M	0.0%	-13.1%	5.810%
2/9/2021	Wells Fargo & Company MN	1,552	$57K	0.0%	+241.1%	0.035%
2/5/2021	BlackRock Inc.	58,168	$2.13M	0.0%	+166.8%	1.328%
11/16/2020	Worth Venture Partners LLC	27,645	$0.21M	0.2%	-21.8%	0.667%
11/9/2020	Acadian Asset Management LLC	45,126	$0.34M	0.0%	-2.5%	1.396%
11/6/2020	GSA Capital Partners LLP	40,512	$0.31M	0.1%	N/A	1.253%

Data available starting January 2016

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Today's Range

Now: $0.21

$0.21

$0.24

50 Day Range

MA: $0.23

$0.14

$0.36

52 Week Range

Now: $0.21

$0.14

$10.80

Volume

715,122 shs

Average Volume

3,788,982 shs

Market Capitalization

$1.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

5.07

Trump’s Back, but DC’s Coming for Your Money!

From Genesis Gold Group | Ad

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov